These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

207 related items for PubMed ID: 10996943

  • 1. [Modern follow-up strategies for the treatment of patients with superficial bladder carcinoma].
    Werner W, Smesny S, Schubert J.
    Z Arztl Fortbild Qualitatssich; 2000 Aug; 94(6):519-27. PubMed ID: 10996943
    [Abstract] [Full Text] [Related]

  • 2. Prognostic factors for primary superficial transitional cell carcinoma of the bladder: a retrospective cohort study.
    Yang TB, Zeng FH, Sun ZQ.
    Chin Med J (Engl); 2006 Nov 05; 119(21):1821-8. PubMed ID: 17097038
    [Abstract] [Full Text] [Related]

  • 3. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
    Stavropoulos NE, Filiadis I, Ioachim E, Hastazeris K, Tsimaris I, Kalogeras D, Stefanaki S, Agnantis NJ.
    Anticancer Res; 2002 Nov 05; 22(6B):3759-64. PubMed ID: 12552989
    [Abstract] [Full Text] [Related]

  • 4. Superficial transitional cell carcinoma of the ureteral orifice: higher risk of developing subsequent upper urinary tract tumors.
    Chou EC, Lin AT, Chen KK, Chang LS.
    Int J Urol; 2006 Jun 05; 13(6):682-5. PubMed ID: 16834642
    [Abstract] [Full Text] [Related]

  • 5. Risk factors for local recurrence in patients with pTa/pT1 urinary bladder cancer.
    Jancke G, Damm O, Rosell J, Jahnson S.
    Scand J Urol Nephrol; 2008 Jun 05; 42(5):417-21. PubMed ID: 18609266
    [Abstract] [Full Text] [Related]

  • 6. Ta T1 low and intermediate transitional cell carcinoma of the bladder: recurrence rates and the timing of check cystoscopies within the first year.
    Guney S, Guney N, Canogullari Z, Ergenekon E.
    Urol Int; 2008 Jun 05; 80(2):124-8. PubMed ID: 18362479
    [Abstract] [Full Text] [Related]

  • 7. Second resection and prognosis of primary high risk superficial bladder cancer: is cystectomy often too early?
    Brauers A, Buettner R, Jakse G.
    J Urol; 2001 Mar 05; 165(3):808-10. PubMed ID: 11176474
    [Abstract] [Full Text] [Related]

  • 8. [A clinical study of recurrence and progression of grade 3 superficial bladder tumor].
    Ikegami S, Tsuji A, Suzuki S, Sumitomo M, Kimura F, Asano T, Nakajima F, Hayakawa M.
    Hinyokika Kiyo; 1999 May 05; 45(5):325-9. PubMed ID: 10410314
    [Abstract] [Full Text] [Related]

  • 9. Follow-up of patients with noninvasive and superficially invasive bladder cancer.
    Holmäng S.
    Semin Urol Oncol; 2000 Nov 05; 18(4):273-9. PubMed ID: 11101090
    [Abstract] [Full Text] [Related]

  • 10. Twelve-year follow up of a randomized prospective trial comparing bacillus Calmette-Guerin and epirubicin as adjuvant therapy in superficial bladder cancer.
    Cheng CW, Chan SF, Chan LW, Chan CK, Ng CF, Cheung HY, Chan SY, Wong WS, Lai FM, To KF, Li ML.
    Int J Urol; 2005 May 05; 12(5):449-55. PubMed ID: 15948743
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Clinical panurothelial disease in patients with superficial bladder tumors: therapeutic implications.
    Solsona E, Iborra I, Ricos JV, Monros JL, Rubio J, Almenar S.
    J Urol; 2002 May 05; 167(5):2007-11. PubMed ID: 11956428
    [Abstract] [Full Text] [Related]

  • 15. A surveillance schedule for G1Ta bladder cancer allowing efficient use of check cystoscopy and safe discharge at 5 years based on a 25-year prospective database.
    Mariappan P, Smith G.
    J Urol; 2005 Apr 05; 173(4):1108-11. PubMed ID: 15758711
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Results of radical cystectomy for management of invasive bladder cancer with special reference to prognostic factors and quality of life depending on the type of urinary diversion].
    Słojewski M.
    Ann Acad Med Stetin; 2000 Apr 05; 46():217-29. PubMed ID: 11712306
    [Abstract] [Full Text] [Related]

  • 18. [Results of adjuvant intravesical Bacillus Calmette-Guérin therapy for grade 3 superficial bladder cancer].
    Yumura Y, Oogo Y, Takase K, Hamano A, Yamashita Y, Noguchi S, Satomi Y.
    Hinyokika Kiyo; 2004 Nov 05; 50(11):767-71. PubMed ID: 15628536
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Recurrence at three months and high-grade recurrence as prognostic factor of progression in multivariate analysis of T1G2 bladder tumors.
    Palou J, Rodríguez-Rubio F, Millán F, Algaba F, Rodríguez-Faba O, Huguet J, Villavicencio H.
    Urology; 2009 Jun 05; 73(6):1313-7. PubMed ID: 19362341
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.